Evidence map›Paper›PMID 12445679›Full record

ArticleCancer letters2003

Delivery of ribosome-inactivating protein toxin into cancer cells with shock waves.

Tetsuya Kodama, Apostolos G Doukas, Michael R Hamblin

Abstract read
In one paragraph

Article in Cancer letters, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Tetsuya KodamaWEL224, Wellman Laboratories of Photomedicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Apostolos G Doukas
Michael R Hamblin
Massachusetts General Hospital · US

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
Macrophage Targeted Photodynamic TherapyR01CA083882 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2002 to 2004
$740k
NCI NIH HHS R01 CA083882NCI NIH HHS R01 CA/AI838801NIAID NIH HHS R01 AI050875
6 · The paper itself

Abstract

We report on the use of shock waves delivered by a shock-tube to permeabilize cancer cells and potentiate the cytotoxicity of the type-1 ribosome-inactivating protein, saporin. We studied human colorectal cancer HT29 and ovarian cancer OVCAR-5 cells, and used two different cytotoxicity assays, colony formation and loss of mitochondrial activity. A single shock wave and saporin (10(-9) M) produced significant toxicity not seen with either shock wave or drug alone. Increasing the number of shock waves up to five further increased cytotoxicity. Higher toxicity was seen with the clonogenic assay compared to MTT assay. Shock waves may have applications in promoting cytoplasmic delivery of toxins into cancer cells after intratumoral injection.

Indexed as

High-Energy Shock WavesAntineoplastic Agents, PhytogenicCell SurvivalColony-Forming Units AssayCytological TechniquesFemaleHT29 CellsHumansImmunotoxinsN-Glycosyl HydrolasesOvarian NeoplasmsPlant ProteinsRibosome Inactivating Proteins, Type 1SaporinsTumor Cells, CulturedAntineoplastic Agents, PhytogenicImmunotoxinsN-Glycosyl HydrolasesPlant ProteinsRibosome Inactivating Proteins, Type 1Saporins

Identifiers

PMID12445679
PMCPMC3568984
OpenAlexW1998229588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.